Publications by authors named "Sibang Chen"

3 Publications

  • Page 1 of 1

Corrigendum to "Ovarian metastasis risk factors in endometrial carcinoma: A systematic review and meta-analysis" [Eur J Obstet Gynecol Reprod Biol 267 (2021) 245-255].

Eur J Obstet Gynecol Reprod Biol 2021 Dec 29;269:83. Epub 2021 Dec 29.

Department of Gynecology, Guangxi Medical University First Affiliated Hospital, Nanning, Guangxi, China. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejogrb.2021.12.005DOI Listing
December 2021

Ovarian metastasis risk factors in endometrial carcinoma: A systematic review and meta-analysis.

Eur J Obstet Gynecol Reprod Biol 2021 Dec 13;267:245-255. Epub 2021 Nov 13.

Department of Gynecology, Guangxi Medical University First Affiliated Hospital, Nanning, Guangxi, China. Electronic address:

Objective: To investigate the incidence of ovarian metastasis in endometrial carcinoma (EC) and analyze its risk factors and provide a theoretical basis for whether retention of the ovary in patients with EC.

Methods: A systematic search using synonyms of 'ovarian cancer' and 'metastasis' was conducted in PubMed, Cochrane database, Embase, Google Scholar, and WOS database. Meta-analysis was performed on 7 included studies, comprising 4281 clinical-stage I-IV EC patients. Studies were assessed using the Newcastle-Ottawa Scale (NOS) criteria. Odds risks (OR) and 95% confidence intervals (CI) were calculated using an inverse variance weighted random-effects model.

Results: The ovarian metastasis risk of EC was significantly higher for patients with myometrial invasion >1/2 (OR = 18.19, 95% CI 5.34 to 61.96 compared to myometrial invasion ≤1/2), any pelvic lymph node invasion (PLNI) (OR = 5.41, 95% CI 2.60-10.97 compared to without PLNI), G3 pathological grade (OR = 2.66, 95%CI 1.35-5.24 compared to G1-G2), non-endometrioid pathological type (OR = 6.46, 95% CI 3.25 to 12.83 compared to endometrioid), lymphatic vascular space invasion (LVSI) (OR = 6.46, 95% CI 3.25 to 12.83 compare to without LVSI), age >45 (OR = 2.01, 95% CI 0.29 to 14.11 compared to age ≤45), and cervical invasion (OR = 4.12, 95% CI 1.87 to 9.08 compared to without cervical invasion).

Conclusion: About 4.95% of EC patients develop ovarian metastasis. Age >45, myometrial invasion >1/2, cervical invasion, PLNI, pathological type, G3 pathological grade, and LVSI were the high-risk factors for ovarian metastasis of EC. Ovarian preservation should be carefully selected for patients with EC, and preoperative and intraoperative evaluations should be entirely performed.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejogrb.2021.11.016DOI Listing
December 2021

Diagnostic value of Anti-Mullerian hormone in ovarian granulosa cell tumor: A meta-analysis.

Eur J Obstet Gynecol Reprod Biol 2020 Oct 22;253:266-272. Epub 2020 Aug 22.

Department of Gynecology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Province, 530022, China. Electronic address:

Background: Granulosa cell tumor (GCT) is a rare type of ovarian malignancy with poor prognosis of recurrence. Anti-Mullerian hormone (AMH) is a promising serum biomarker for early diagnosis GCT, therefore we assessed its accuracy and clinical value.

Methods: A meta-analysis was performed to estimate the diagnostic accuracy. We searched the PubMed, Cochrane Literature Library and EMBASE database. After filtering, five studies met our criteria. Two independent reviewers extracted data and total 421 serum samples (70 GCT serum samples and 351 controls) were included in our analysis. The pooled values of sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and Summary receiver operating characteristic (SROC) were calculated to assess the accuracy.

Results: The pooled estimated for AMH were sensitivity: 0.89 (95 % CI 0.78-0.95), specificity: 0.93 (95 %CI 0.83-0.97). The area under the SROC was 0.93 (95 %CI 0.91-0.95).

Conclusion: Serum AMH can be used as a biomarker in clinical diagnosis of GCT with high accuracy.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejogrb.2020.08.011DOI Listing
October 2020
-->